CONBA(SH:600572) Zheng Quan Zhi Xing·2025-06-13 09:42Core Viewpoint - The legal opinion letter issued by Shanghai Dongfang Huayin Law Firm confirms that Zhejiang Kang En Bei Pharmaceutical Co., Ltd. has complied with relevant laws and regulations regarding the adjustment of the exercise price for its 2022 stock option incentive plan [1][8]. Group 1: Company Qualifications - The company is a legally established joint-stock company listed on the Shanghai Stock Exchange, with a total share capital of 137.2 million shares, including 40 million A-shares [3]. - The company does not fall under any prohibitive conditions for implementing stock incentives as outlined in the Management Measures [4]. Group 2: Approval and Authorization - The company has completed the necessary approval and authorization procedures for adjusting the exercise price of the stock options under the 2022 incentive plan, in accordance with the Management Measures and the incentive plan [5][8]. Group 3: Adjustment Details - The exercise price for the stock options has been adjusted from 3.78 yuan to 3.63 yuan per share for the first grant, and from 5.07 yuan to 4.92 yuan per share for the reserved grant, following the company's profit distribution plan [6][8].